253 related articles for article (PubMed ID: 12698985)
21. Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
Ha HR; Chen J; Freiburghaus AU; Follath F
Br J Clin Pharmacol; 1995 Mar; 39(3):321-6. PubMed ID: 7619675
[TBL] [Abstract][Full Text] [Related]
22. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
23. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
24. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
Ghobadi C; Johnson TN; Aarabi M; Almond LM; Allabi AC; Rowland-Yeo K; Jamei M; Rostami-Hodjegan A
Clin Pharmacokinet; 2011 Dec; 50(12):809-22. PubMed ID: 22087867
[TBL] [Abstract][Full Text] [Related]
25. Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.
Yokoi T
J Toxicol Sci; 2009; 34 Suppl 2():SP307-12. PubMed ID: 19571484
[TBL] [Abstract][Full Text] [Related]
26. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.
Salem F; Johnson TN; Abduljalil K; Tucker GT; Rostami-Hodjegan A
Clin Pharmacokinet; 2014 Jul; 53(7):625-36. PubMed ID: 24671884
[TBL] [Abstract][Full Text] [Related]
27. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.
Tomalik-Scharte D; Jetter A; Kinzig-Schippers M; Skott A; Sörgel F; Klaassen T; Kasel D; Harlfinger S; Doroshyenko O; Frank D; Kirchheiner J; Bräter M; Richter K; Gramatté T; Fuhr U
Drug Metab Dispos; 2005 Dec; 33(12):1859-66. PubMed ID: 16183781
[TBL] [Abstract][Full Text] [Related]
28. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
[TBL] [Abstract][Full Text] [Related]
29. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
[TBL] [Abstract][Full Text] [Related]
30. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
Galetin A; Houston JB
J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
[TBL] [Abstract][Full Text] [Related]
31. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
[TBL] [Abstract][Full Text] [Related]
32. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
[TBL] [Abstract][Full Text] [Related]
33. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
Rogers JF; Nafziger AN; Bertino JS
Am J Med; 2002 Dec; 113(9):746-50. PubMed ID: 12517365
[TBL] [Abstract][Full Text] [Related]
35. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
36. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
37. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Bournique B; Lambert N; Boukaiba R; Martinet M
Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
[TBL] [Abstract][Full Text] [Related]
38. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
40. The immature rat as a potential model for chemical risks to children: Ontogeny of selected hepatic P450s.
McPhail BT; White CA; Cummings BS; Muralidhara S; Wilson JT; Bruckner JV
Chem Biol Interact; 2016 Aug; 256():167-77. PubMed ID: 27387539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]